These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 25043770)

  • 1. An analysis of FDA-approved drugs for infectious disease: antibacterial agents.
    Kinch MS; Patridge E; Plummer M; Hoyer D
    Drug Discov Today; 2014 Sep; 19(9):1283-7. PubMed ID: 25043770
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Progress in the Fight Against Multidrug-Resistant Bacteria? A Review of U.S. Food and Drug Administration-Approved Antibiotics, 2010-2015.
    Deak D; Outterson K; Powers JH; Kesselheim AS
    Ann Intern Med; 2016 Sep; 165(5):363-72. PubMed ID: 27239977
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An analysis of FDA-approved drugs for infectious disease: HIV/AIDS drugs.
    Kinch MS; Patridge E
    Drug Discov Today; 2014 Oct; 19(10):1510-3. PubMed ID: 24880109
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An analysis of FDA-approved drugs for inflammation and autoimmune diseases.
    Kinch MS; Merkel J
    Drug Discov Today; 2015 Aug; 20(8):920-3. PubMed ID: 25701283
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An analysis of FDA-approved drugs: natural products and their derivatives.
    Patridge E; Gareiss P; Kinch MS; Hoyer D
    Drug Discov Today; 2016 Feb; 21(2):204-7. PubMed ID: 25617672
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Trends in antimicrobial drug development: implications for the future.
    Spellberg B; Powers JH; Brass EP; Miller LG; Edwards JE
    Clin Infect Dis; 2004 May; 38(9):1279-86. PubMed ID: 15127341
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Availability of comparative efficacy data at the time of drug approval in the United States.
    Goldberg NH; Schneeweiss S; Kowal MK; Gagne JJ
    JAMA; 2011 May; 305(17):1786-9. PubMed ID: 21540422
    [TBL] [Abstract][Full Text] [Related]  

  • 8. FDA approves first drug in new class of antibiotics.
    Senior K
    Lancet; 2000 Apr; 355(9214):1523. PubMed ID: 10801180
    [No Abstract]   [Full Text] [Related]  

  • 9. Effective Market Exclusivity of New Molecular Entities for Rare and Non-rare Diseases.
    Kerr KW; Glos LJ
    Pharmaceut Med; 2020 Feb; 34(1):19-29. PubMed ID: 32048213
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An analysis of FDA-approved drugs for metabolic diseases.
    Kinch MS; Umlauf S; Plummer M
    Drug Discov Today; 2015 Jun; 20(6):648-51. PubMed ID: 25680688
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An analysis of FDA-approved drugs for neurological disorders.
    Kinch MS
    Drug Discov Today; 2015 Sep; 20(9):1040-3. PubMed ID: 25681791
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Model-Informed Drug Development for Anti-Infectives: State of the Art and Future.
    Rayner CR; Smith PF; Andes D; Andrews K; Derendorf H; Friberg LE; Hanna D; Lepak A; Mills E; Polasek TM; Roberts JA; Schuck V; Shelton MJ; Wesche D; Rowland-Yeo K
    Clin Pharmacol Ther; 2021 Apr; 109(4):867-891. PubMed ID: 33555032
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Trends in pharmaceutical targeting of clinical indications: 1930-2013.
    Kinch MS; Merkel J; Umlauf S
    Drug Discov Today; 2014 Nov; 19(11):1682-1685. PubMed ID: 24881779
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The potential risks of expedited approval of drugs for acute bacterial infections.
    Floyd JS; Psaty BM
    JAMA Intern Med; 2014 Sep; 174(9):1436-7. PubMed ID: 25023994
    [No Abstract]   [Full Text] [Related]  

  • 15. Design and Discovery of New Antibacterial Agents: Advances, Perspectives, Challenges.
    Jampilek J
    Curr Med Chem; 2018; 25(38):4972-5006. PubMed ID: 28925868
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Establishing a list of qualifying pathogens under the Food and Drug Administration Safety and Innovation Act. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2014 Jun; 79(108):32464-81. PubMed ID: 24908687
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New antimicrobial agents approved by the U.S. Food and Drug Administration in 1999 and new indications for previously approved agents.
    Antimicrob Agents Chemother; 2000 Apr; 44(4):1114-5. PubMed ID: 10722527
    [No Abstract]   [Full Text] [Related]  

  • 18. Preserving the lifesaving power of antimicrobial agents.
    Hughes JM
    JAMA; 2011 Mar; 305(10):1027-8. PubMed ID: 21343545
    [No Abstract]   [Full Text] [Related]  

  • 19. 2018 in review: FDA approvals of new molecular entities.
    Kinch MS; Griesenauer RH
    Drug Discov Today; 2019 Sep; 24(9):1710-1714. PubMed ID: 31158510
    [TBL] [Abstract][Full Text] [Related]  

  • 20. What do the new antimicrobials offer? Weighing the advantages and disadvantages compared with traditional agents.
    Gleckman R
    Postgrad Med; 2001 Mar; 109(3):87-91; quiz 28. PubMed ID: 11265366
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.